Author
Youn-Chul Kim
Other affiliations: Woosuk University
Bio: Youn-Chul Kim is an academic researcher from Wonkwang University. The author has contributed to research in topics: Heme oxygenase & Nitric oxide synthase. The author has an hindex of 48, co-authored 339 publications receiving 8272 citations. Previous affiliations of Youn-Chul Kim include Woosuk University.
Papers published on a yearly basis
Papers
More filters
TL;DR: It is suggested that curcumin reduced the MICs of several antibiotics tested, notably of OXI, AMP, CIP, and NOR, and that CCM in combination with antibiotics could lead to the development of new combination of antibiotics against MRSA infection.
320 citations
TL;DR: The results support the use of this plant for the treatment of hepatitis in oriental traditional medicine.
165 citations
TL;DR: Treatment of hepatocytes with ENN inhibited both the production of serum enzymes and cytotoxicity by CCl4 and AFB1, suggesting hepatoprotective effects of ENN might result from its potent antioxidative properties.
158 citations
TL;DR: Results suggest that alantolactone exerts its anti-inflammatory effect in LPS-stimulated RAW 264.7 cells by suppressing NF-κB activation and MAPKs phophorylation via downregulation of the MyD88 signaling pathway, and may provide a useful therapeutic approach for inflammation-associated diseases.
156 citations
TL;DR: Results indicated that resveratrol exerted a regulatory effect on inflammatory reactions mediated by mast cells.
129 citations
Cited by
More filters
TL;DR: This review covers the literature published in 2014 for marine natural products, with 1116 citations referring to compounds isolated from marine microorganisms and phytoplankton, green, brown and red algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, mangroves and other intertidal plants and microorganisms.
4,649 citations
TL;DR: Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.
Abstract: Purpose: Pancreatic cancer is almost always lethal, and the only U.S. Food and Drug Administration–approved therapies for it, gemcitabine and erlotinib, produce objective responses in Experimental Design: Patients received 8 g curcumin by mouth daily until disease progression, with restaging every 2 months. Serum cytokine levels for interleukin (IL)-6, IL-8, IL-10, and IL-1 receptor antagonists and peripheral blood mononuclear cell expression of NF-κB and cyclooxygenase-2 were monitored. Results: Twenty-five patients were enrolled, with 21 evaluable for response. Circulating curcumin was detectable as drug in glucuronide and sulfate conjugate forms, albeit at low steady-state levels, suggesting poor oral bioavailability. Two patients showed clinical biological activity. One had ongoing stable disease for >18 months; interestingly, one additional patient had a brief, but marked, tumor regression (73%) accompanied by significant increases (4- to 35-fold) in serum cytokine levels (IL-6, IL-8, IL-10, and IL-1 receptor antagonists). No toxicities were observed. Curcumin down-regulated expression of NF-κB, cyclooxygenase-2, and phosphorylated signal transducer and activator of transcription 3 in peripheral blood mononuclear cells from patients (most of whom had baseline levels considerably higher than those found in healthy volunteers). Whereas there was considerable interpatient variation in plasma curcumin levels, drug levels peaked at 22 to 41 ng/mL and remained relatively constant over the first 4 weeks. Conclusions: Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.
1,173 citations
TL;DR: This review focuses on the status of all these approaches in generating a "super curcumin," a homodimer of feruloylmethane containing a methoxy group and a hydroxyl group, a heptadiene with two Michael acceptors, and an alpha,beta-diketone.
1,095 citations
TL;DR: The activity of curcumin reported against leukemia and lymphoma, gastrointestinal cancers, genitourinary cancers, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, melanoma, neurological cancers, and sarcoma reflects its ability to affect multiple targets.
1,014 citations